** Shares of cosmetic drugmaker Evolus EOLS.O rise 3.7% to $14.88 in extended trade
** Co reports adjusted income of $6.7 million in Q4, compared with a year-ago loss of $3.7 million
** EOLS sees 2025 rev between $345 million and $355 million, versus Wall Street estimates of $351.3 million — LSEG
** Co says annual net revenue can reach at least $700 million by 2028
** EOLS rose 4.8% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.